Arrivent Biopharma Inc.

3 trials 2 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

5 Countries active

6 Unique IMPs

100% Results reported

Phase III

Phase I (Other)

Phase III: 2 Phase I (Other): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 HER2 mutant non-small cell lung cancer 1 Non-small cell lung cancer metastatic 1

Top IMPs

N-[2-[2-(DIMETHYLAMINO)ETHYL-METHYLAMINO]-5-[[4-(1-METHYLINDOL-3-YL)PYRIMIDIN-2-YL]AMINO]-6-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-3-YL]PROP-2-ENAMIDE 2 CARBOPLATIN 1 CISPLATIN 1 PEMETREXED 1

All trials

3 total

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with A… Recruiting

2023-508349-42-00 Phase I (Other) 4 countries
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part… Recruiting

2025-522151-26-00 Phase III 4 countries N-[2-[2-(DIMETHYLAMINO)ETHYL-METHYLAMINO]-5-[[4-(1-METHYLINDOL-3-YL)PYRIMIDIN-2-…
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL… Ended

2022-502977-41-00 Phase III 4 countries CARBOPLATIN; CISPLATIN; N-[2-[2-(DIMETHYLAMINO)ETHYL-METHYLAMINO]-5-[[4-(1-METHY…

Showing 1–3 of 3 trials

← All sponsors A–Z